Phase 3 topline

Primary completion of A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease

OCGN · Ocugen, Inc. · OCU410ST · Stargardt Disease

Date
2026-09-28
Exact day · Estimated
In 7d
As stated: “2026-09-28
Research probability
This event is not joined to a researched indication.
Runway vs event
Cash or burn is missing, so no runway verdict is made.
Model value at stake
Research for this company needs an account. The sample companies are fully interactive without one.

Sources and detail

Float
No public float has been reported at a usable date.
Stake
Research for this company needs an account. The sample companies are fully interactive without one.
Runway vs event
Cash or burn is missing, so no runway verdict is made.
Financing
No financing filing in the period covered.
Specialist holders
No specialist 13F quarter has been read for this issuer.
Insider net 90d
No open-market insider transaction was filed in the window.

What happened

Ahead of its window

The stated window has not opened yet.

Sources (1)

  • ClinicalTrials.gov · NCT05956626

    clinicaltrials gov · published 2026-07-31 · retrieved 2026-09-21

    primaryCompletionDateStruct: {"date": "2026-09-28", "type": null}

Research

This event is not joined to a researched indication.

Research date unknown

Market

Market linking is switched off.

Quotes elsewhere

This desk holds no price. These go to the venues that publish one.

What counts as each outcome

Resolved by the sponsor's topline disclosure of the trial's primary endpoint: met with statistical significance is success; missed is failure; co-primary endpoints split, or significance reached only in a pre-specified subgroup, is mixed.

Missing inputs

  • issuer_facts: not collected
  • public_float_usd: not collected
  • shares_outstanding: not collected
  • cash_and_investments: not collected
  • operating_cash_flow: not collected
  • quarterly_burn: not collected
  • runway_quarters: not collected

Event row last changed 2026-09-21 · filing signals evaluated 2026-09-21

What changed on this event

  1. · created · event · — → Primary completion of A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease · clinicaltrials_gov-candidate
  2. · status · review_state · pending → published · government-source

This is a dated event and its evidence, not a forecast of its outcome. No price, implied move or market probability is collected or shown anywhere on this page.

Share this event

$OCGN Phase 3 topline — 28 Sep 2026 (estimated). The date, its source and every figure behind it: https://getfuzebio.com/catalysts/ocgn-ocu410st-phase3-topline-71e9ea3e?utm_source=x&utm_medium=social&utm_campaign=event&utm_content=event-ev_71e9ea3ed5d9967c

The card this link unfurls to — it carries the date, its confidence and the figures above, and nothing that is not on this page.

Canonical link: https://getfuzebio.com/catalysts/ocgn-ocu410st-phase3-topline-71e9ea3e

Composed 2026-09-21 · event table maintained 2026-09-21. Assembling this page is not evidence that the sources under it were re-read.